Literature DB >> 486313

An approach to the problem of heterogeneity of human tumour-cell populations.

J Sirachý.   

Abstract

1. Successive sampling of ovarian cancers during cytostatic treatment showed several cases of notable changes in their ploidy distribution and one change in model chromosome number, indicating selection of a resistant tumour-cell population. 2. Studies of cell suspensions from human tumour specimens incubated with [3H]-TdR after exposure in vitro to various cytostatic agents have shown variation in labelling between different parts of the same tumour, as well as between the primary tumour and its metastases or ascitic tumour-cell population, which may be accounted for by variation in sensitivity of the tumour-cell population. 3. Studies of nuclear morphology in 20 endometrial cancers before and after progesterone therapy demonstrate considerable variation in the proportion of cells undergoing secretory conversion within the same tumour, indicating primary heterogeneity of the tumour-cell population in response to progesterone.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 486313      PMCID: PMC2009909          DOI: 10.1038/bjc.1979.103

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs.

Authors:  C Tropé; L Håkansson; H Dencker
Journal:  Neoplasma       Date:  1975       Impact factor: 2.575

2.  Drug sensitivity studies on clonal cell lines isolated from heteroploid tumour cell populations. I. Dose response of clones growing in monolayer cultures.

Authors:  I Pályi; E Oláh; J Sugár
Journal:  Int J Cancer       Date:  1977-06-15       Impact factor: 7.396

3.  Chromosomal examination of various cell clones (in vitro) derived from a DMBA (7-12 dimethyl-alpha-benzanthracene)-induced male rat breast tumour.

Authors:  N P Bishun; J Mills; N Lloyd; D C Williams
Journal:  Eur J Cancer       Date:  1973 Nov-Dec       Impact factor: 9.162

4.  The chromosomes of fifty primary Rous rat sarcomas.

Authors:  F Mitelman
Journal:  Hereditas       Date:  1971       Impact factor: 3.271

5.  [Cytogenic and karyological studies of clinically treated gynecological tumors].

Authors:  J Eicke; A Emminger; C Strauss; U Mohr; H Wrba
Journal:  Z Krebsforsch       Date:  1965

6.  On the presence within tumours of clones that differ in sensitivity to cytostatic drugs.

Authors:  L Håkansson; C Tropé
Journal:  Acta Pathol Microbiol Scand A       Date:  1974-01

7.  An in vitro study of cytostatic drug effect on the drug effect on the DNA synthesis in methylcholanthrene induced mouse sarcomas. Correlation between in vitro results and the response in vivo.

Authors:  C Tropé; L Håkansson
Journal:  Acta Pathol Microbiol Scand A       Date:  1974-03

8.  The cytogenetic effect of cyclophosphamide on a Burkitt tumour cell line (EB4) in vitro.

Authors:  N P Bishun
Journal:  Mutat Res       Date:  1971-02       Impact factor: 2.433

9.  Endometrial morphology in women exposed to uterine systems releasing progesterone.

Authors:  J Martínez-Manautou; M Maqueo; R Aznar; B B Pharriss; A Zaffaroni
Journal:  Am J Obstet Gynecol       Date:  1975-01-15       Impact factor: 8.661

10.  Morphology and DNA content of endometrial cancer nuclei under progestogen treatment.

Authors:  J Hustin
Journal:  Acta Cytol       Date:  1976 Nov-Dec       Impact factor: 2.319

View more
  10 in total

1.  Biological heterogeneity and radiation sensitivity of in vitro propagated lung metastatic lines originated from a transplantable squamous cell carcinoma of BALB/c mouse.

Authors:  R J Jamasbi; E H Perkins
Journal:  In Vitro Cell Dev Biol       Date:  1990-03

2.  Tumor heterogeneity: biological implications and therapeutic consequences.

Authors:  G H Heppner; B E Miller
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

3.  The selective nature of metastasis.

Authors:  J E Talmadge
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

4.  The clinical significance of regional variations in histologic differentiation within carcinomas of the colorectum.

Authors:  H Kotanagi; T Fukuoka; Y Shibata; T Yoshioka; O Aizawa; K Koyama
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

5.  Cancer: crab or chimera? The clinical implications of cancer cell heterogeneity.

Authors:  P Calabresi
Journal:  Trans Am Clin Climatol Assoc       Date:  1981

6.  Anticancer chemosensitivity changes between the original and recurrent tumors after successful chemotherapy selected according to the sensitivity assay.

Authors:  Y Nio; K Tamura; M Tsubono; K Kawabata; Y Masai; H Hayashi; S Ishigami; S Araya; M Imamura
Journal:  Ann Surg       Date:  1995-01       Impact factor: 12.969

Review 7.  Some aspects of size-dependent differential drug response in primary and metastatic tumors.

Authors:  I Abe; M Suzuki; K Hori; S Saito; H Sato
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

8.  Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts.

Authors:  R Giavazzi; A Garofalo; G Damia; S Garattini; M D'Incalci
Journal:  Br J Cancer       Date:  1988-03       Impact factor: 7.640

Review 9.  Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer.

Authors:  Sarah P Blagden
Journal:  Front Oncol       Date:  2015-06-30       Impact factor: 6.244

10.  Intra-tumoral heterogeneity of tumour potential doubling times (Tpot) in colorectal cancer.

Authors:  M S Wilson; C M West; G D Wilson; S A Roberts; R D James; P F Schofield
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.